News AstraZeneca PLC Deutsche Boerse AG

Stocks

ZEG

GB0009895292

Pharmaceuticals

Real-time Estimate Tradegate 14:10:22 2026-09-11 EDT			5-day change	1st Jan Change
137.50 ^EUR	+0.26%		-2.03%	-13.20%

10:53am	Odin Norden rose 3.15 percent in August - Valmet jumped on break-up plans	FW
09:23am	Carnegie All Cap rose 0.83 percent in August, solid risk appetite	FW

All News

Mentions Relevance

09-10	Berenberg Notes AstraZeneca's 'Stellar' Tozorakimab Late-stage Data; Buy Retained	MT
09-10	AstraZeneca PLC : Gets a Sell rating from Deutsche Bank	ZD
09-10	AstraZeneca PLC : Berenberg reiterates its Buy rating	ZD
09-09	RBC Capital Markets Initiates AstraZeneca Coverage at Outperform	MT
09-09	HEALTH ROUNDS-AstraZeneca drug reduces lung disease flare-ups in late-stage trials	RE
09-09	RBC Initiates AstraZeneca at Outperform With GBP145 Price Target	MT
09-09	RBC Initiates AstraZeneca at Outperform as Near-term Overhangs Create 'Attractive' Entry Point	MT
09-08	AstraZeneca PLC : Gets a Buy rating from RBC	ZD
09-08	AstraZeneca PLC Presents at European Respiratory Society Congress, Sep-08-2026 05:00 PM
09-08	AstraZeneca Demonstrates Statistically Significant And Clinically Meaningful Improvement In Overall Survival And Progression-Free Survival With IMFINZI Plus Tarlatamab In First-Line Extensive-Stage Small Cell Lung Cancer	CI
09-08	AstraZeneca PLC : Buy rating from JP Morgan	ZD
09-08	AstraZeneca and Amgen clear a milestone in small cell lung cancer
09-08	Correction to AstraZeneca Article	DJ
09-08	Amgen-AstraZeneca drug combo helps lung cancer patients live longer in late-stage study	RE
09-08	AstraZeneca's Imfinzi Combo Therapy Boosts Survival in Late-stage Small Cell Lung Cancer Study	MT
09-08	AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groups	DJ
09-08	IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer	BU
09-08	AstraZeneca Says Tozorakimab Cuts COPD Exacerbations in Phase 3 Trials	MT
09-08	AstraZeneca Demonstrates Statistically Significant Reduction In COPD Exacerbations With Tozorakimab In OBERON And TITANIA Phase III Trials	CI
09-08	AstraZeneca's Tozorakimab Shows Statistically Significant Efficacy in Late-stage Trials	MT
09-08	AstraZeneca moves forward in COPD
09-08	Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials	BU
09-08	AstraZeneca : Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials	PU
09-08	AstraZeneca PLC : Receives a Sell rating from Deutsche Bank	ZD
09-08	AstraZeneca PLC : Barclays maintains a Buy rating	ZD